1
|
Casanova N, Beaulieu K, Oustric P, O’Connor D, Gibbons C, Blundell J, Finlayson G, Hopkins M. The inhibitory effect of FAT mass on energy intake is weakened by the accumulation of body fatness. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
2
|
Bird D, Teo M, Casanova N, Cooper R, Gilbert A, Mccallum H, Sebag-Montefiore D, Henry A, Speight R, Al-Qaisieh B, Nix M. PH-0410: Multi-centre, deep learning, sCT generation for anorectal cancers with AI robustness assessment. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00432-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
3
|
Leiva CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials. Int Immunopharmacol 2020. [PMID: 32036273 DOI: 10.1016/j.intimp.2020.106269.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
Abstract
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010-2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases.
Collapse
Affiliation(s)
- Carlos Leónidas Leiva
- Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina; Instituto de Patobiología Veterinaria, UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
| | - M Julián Gallardo
- Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina; Instituto de Patobiología Veterinaria, UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
| | - Natalia Casanova
- Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina; Instituto de Patobiología Veterinaria, UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
| | - Horacio Terzolo
- Estación Experimental Agropecuaria Balcarce, Instituto Nacional de Tecnología Agropecuaria, RN 226 Km 73.3, Balcarce, Buenos Aires, Argentina.
| | - Pablo Chacana
- Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina; Instituto de Patobiología Veterinaria, UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
| |
Collapse
|
4
|
Beaulieu K, Casanova N, Oustric P, Gibbons C, Hopkins M, Varady K, Blundell J, Finlayson G. OR47: Matched Weight Loss Through Intermittent or Continuous Energy Restriction Does not Result in Compensatory Adaptations in Appetite: A Proof of Concept RCT. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32519-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Casanova N, Beaulieu K, Oustric P, Gibbons C, Finlayson G, Hopkins M. SUN-LB669: Reductions in Physical Activity Attenuate the Rate of Weight Loss During Dietary Energy Restriction in Women with Overweight and Obesity. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32635-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Motiño O, Francés DE, Casanova N, Fuertes-Agudo M, Cucarella C, Flores JM, Vallejo-Cremades MT, Olmedilla L, Pérez Peña J, Bañares R, Boscá L, Casado M, Martín-Sanz P. Protective Role of Hepatocyte Cyclooxygenase-2 Expression Against Liver Ischemia-Reperfusion Injury in Mice. Hepatology 2019; 70:650-665. [PMID: 30155948 DOI: 10.1002/hep.30241] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 08/22/2018] [Indexed: 02/05/2023]
Abstract
Liver ischemia and reperfusion injury (IRI) remains a serious clinical problem affecting liver transplantation outcomes. IRI causes up to 10% of early organ failure and predisposes to chronic rejection. Cyclooxygenase-2 (COX-2) is involved in different liver diseases, but the significance of COX-2 in IRI is a matter of controversy. This study was designed to elucidate the role of COX-2 induction in hepatocytes against liver IRI. In the present work, hepatocyte-specific COX-2 transgenic mice (hCOX-2-Tg) and their wild-type (Wt) littermates were subjected to IRI. hCOX-2-Tg mice exhibited lower grades of necrosis and inflammation than Wt mice, in part by reduced hepatic recruitment and infiltration of neutrophils, with a concomitant decrease in serum levels of proinflammatory cytokines. Moreover, hCOX-2-Tg mice showed a significant attenuation of the IRI-induced increase in oxidative stress and hepatic apoptosis, an increase in autophagic flux, and a decrease in endoplasmic reticulum stress compared to Wt mice. Interestingly, ischemic preconditioning of Wt mice resembles the beneficial effects observed in hCOX-2-Tg mice against IRI due to a preconditioning-derived increase in endogenous COX-2, which is mainly localized in hepatocytes. Furthermore, measurement of prostaglandin E2 (PGE2 ) levels in plasma from patients who underwent liver transplantation revealed a significantly positive correlation of PGE2 levels and graft function and an inverse correlation with the time of ischemia. Conclusion: These data support the view of a protective effect of hepatic COX-2 induction and the consequent rise of derived prostaglandins against IRI.
Collapse
Affiliation(s)
- Omar Motiño
- Instituto de Investigaciones Biomédicas "Alberto Sols," CSIC-UAM, Madrid, Spain
| | - Daniel E Francés
- Instituto de Fisiología Experimental (IFISE-CONICET), Rosario, Argentina
| | - Natalia Casanova
- Instituto de Investigaciones Biomédicas "Alberto Sols," CSIC-UAM, Madrid, Spain
| | | | - Carme Cucarella
- Instituto de Biomedicina de Valencia, IBV-CSIC, Valencia, Spain
| | - Juana M Flores
- Department of Animal Medicine and Surgery, Veterinary Faculty, Universidad Complutense de Madrid, Spain
| | | | - Luis Olmedilla
- Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain
| | - José Pérez Peña
- Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain
| | - Rafael Bañares
- Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain
- Medicine Faculty, Universidad Complutense de Madrid, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
| | - Lisardo Boscá
- Instituto de Investigaciones Biomédicas "Alberto Sols," CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERcv), Madrid, Spain
| | - Marta Casado
- Instituto de Biomedicina de Valencia, IBV-CSIC, Valencia, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERcv), Madrid, Spain
| | - Paloma Martín-Sanz
- Instituto de Investigaciones Biomédicas "Alberto Sols," CSIC-UAM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERcv), Madrid, Spain
| |
Collapse
|
7
|
Nix M, Ward G, Goody R, Lilley J, Casanova N, Garratt R, Picken K, Al-Qaisieh B. EP-1954 The role of 4D cone beam CT and abdominal compression in motion management for Liver SABR. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32374-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Janjua T, Hingorani M, Cooper R, Hatfield P, Casanova N, Williams M, Teo M, Sebag-Montefiore D. The role of palliative re-irradiation in management of rectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Jones C, Murray P, Goody R, Ward G, Casanova N, Hatfield P, Radhakrishna G. EP-1452: Safety & tolerability of radiotherapy dose escalation in cervical-upper thoracic oesophageal cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31761-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
López Nigro M, Casanova N, Carballo M. Genotoxic and protective effects of glucosinolates. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Speight R, Franks K, Henry A, Casanova N, Cosgrove V, Lilley J. Producing a VMAT Class Solution for Adjuvant Pelvic Radiation Therapy for Penile Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Betz M, Zilli T, Casanova N, Rouzaud M, Nouet P, Dipasquale G, Miralbell R, Ozsahin M. Optimisation dosimétrique par radiothérapie conformationnelle avec modulation d’intensité employant une méthode simple utilisant deux faisceaux dans l’irradiation unilatérale de cancers de la sphère ORL. Cancer Radiother 2009. [DOI: 10.1016/j.canrad.2009.08.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Ozsahin M, Casanova N, Pachoud M, Moeckli R, Dipasquale G, Nouet P, Rouzaud M, Allal A, Zouhair A, Zilli T. 6027 Helical tomotherapy or intensity-modulated radiation therapy in the treatment of anal cancer: experience of Geneva and Lausanne. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71122-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Casanova N, Magné N, Chajon E, Morice P, Lhommé C, Castaigne D, Haie-Meder C. Curiethérapie dans les cancers du col utérin chez les patientes âgées. Cancer Radiother 2006. [DOI: 10.1016/j.canrad.2006.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Verges R, Benavente S, Garcia A, Hermosilla E, Casanova N, Ramos M, Gil-Moreno A, Giralt J. 2691. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.1106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Casanova N, McGuire E, Fenner DE. Botulinum toxin: A potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity. Int J Gynaecol Obstet 2006; 95:305-11. [PMID: 17070528 DOI: 10.1016/j.ijgo.2006.08.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/30/2006] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To analyze and report the current data on the treatment of both neurogenic and idiopathic detrusor overactivity with Botulinum toxin. METHODS Literature review using Pub-Med and Medline from 1990 until June 30, 2006. RESULTS Case series of patients with neurogenic detrusor dysfunction (NDD) and idiopathic detrusor overactivity (IDO) range from 15 to 200 patients with follow up from 12 to 36 weeks post-treatment. Significant improvements in cystometric bladder capacity, reflex volume at first urge to void, and bladder compliance are seen in nearly all patients. Approximately 50% of NDD patients achieved urinary continence and almost all had improvement in bladder control up to 36 weeks following treatment. Patients with IDO with urgency alone or with incontinence also had urodynamic as well as symptom improvement. Approximately 75% of patients with IDO and incontinence are dry at 12 weeks post-treatment. Urgency disappears on average in two thirds of patients. Quality of life scores also shows significant improvement for all groups. CONCLUSION Botulinum toxin-A has emerged as a promising option for the treatment of neurogenic and refractory idiopathic detrusor overactivity. Studies to date have shown that not only is this treatment effective at decreasing urinary symptoms and incontinence, as well as improving potentially dangerous urodynamic measures, but it is also minimally invasive, reversible and safe. Questions over proper dosing and dilution, number of injection sites, and re-injection rates remain to be answered.
Collapse
Affiliation(s)
- N Casanova
- University of Michigan, Department of Obstetrics and Gynecology, Ann Arbor, MI, USA
| | | | | |
Collapse
|
17
|
|